Search Result

Results for "

secretagogue

" in MedChemExpress (MCE) Product Catalog:

By Targets:	GHSR (17) Apoptosis (1) Cytochrome P450 (1) Free Fatty Acid Receptor (1) Insulin Receptor (1) Isotope-Labeled Compounds (1) Potassium Channel (4) Ser/Thr Protease (1)
By Research Areas:	Cancer (6) Cardiovascular Disease (2) Endocrinology (9) Inflammation/Immunology (1) Metabolic Disease (14) Neurological Disease (4)

Inhibitors & Agonists

Peptides

Isotope-Labeled Compounds

Antibodies

Targets Recommended: GHSR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15209S

Repaglinide-d5 AG-EE 623ZW d₅	Isotope-Labeled Compounds Potassium Channel	Metabolic Disease
Repaglinide-d₅ is deuterium labeled Repaglinide. Repaglinide is an insulin secretagogue for the treatment of type-2 diabetes mellitus[1].

HY-15209

Repaglinide

AG-EE 623ZW
Potassium Channel Metabolic Disease Cancer

Repaglinide is an insulin secretagogue for the treatment of type-2 diabetes mellitus .

Repaglinide AG-EE 623ZW	Potassium Channel	Metabolic Disease Cancer
Repaglinide is an insulin secretagogue for the treatment of type-2 diabetes mellitus .

HY-50760

L-692585	GHSR	Endocrinology
L-692585 is a potent and nonpeptidyl *growth hormone secretagogue* receptor (GHS-R1a) agonist, with a K_i** of 0.8 nM. L-692585 acts directly on somatotropes causing GH release .

HY-10957

L-692429 MK-0751	GHSR	Metabolic Disease
L-692429 (MK-0751) is a benzolactam derivative and a nonpeptidyl *growth hormone secretagogue* (GHS) agonist. L-692429 binds to G protein-coupled receptor with a K_i** of 63 nM .

HY-W040127

Peonidin 3-O-glucoside chloride	Insulin Receptor	Metabolic Disease
Peonidin 3-O-glucoside chloride, an anthocyanin, act as an insulin secretagogue. Peonidin 3-O-glucoside chloride can increase glucose uptake in HepG2 cells. Peonidin 3-O-glucoside chloride has the potential for type-2 diabetes comorbidities research .

HY-129746

Arylquin 1	Apoptosis	Cancer
Arylquin 1, a prostate-apoptosis-response-4 (Par-4) secretagogue, targets vimentin to induce Par-4 secretion. Arylquin 1 induces non-apoptotic cell death in cancer cells through the induction of lysosomal membrane permeabilization (LMP) .

HY-14495

BMS-604992 EX-1314	GHSR	Metabolic Disease
BMS-604992 (EX-1314) is a selective, orally active small-molecule *growth hormone secretagogue* receptor (GHSR) agonist. BMS-604992 demonstrates high-affinity binding (K_i=2.3 nM) and potent functional activity (EC₅₀**=0.4 nM). BMS-604992 can stimulate food intake in rodents .

HY-14495B

BMS-604992 dihydrochloride EX-1314 dihydrochloride	GHSR	Metabolic Disease
BMS-604992 (EX-1314) dihydrochloride is a selective, orally active small-molecule *growth hormone secretagogue* receptor (GHSR) agonist. BMS-604992 dihydrochloride demonstrates high-affinity binding (k_i=2.3 nM) and potent functional activity (EC₅₀**=0.4 nM). BMS-604992 dihydrochloride can stimulate food intake in rodents .

HY-19884A

Relamorelin acetate RM-131 acetate; BIM-28131 acetate	GHSR	Metabolic Disease
Relamorelin (RM-131) acetate, a pentapeptide ghrelin analog, is a selective *ghrelin/growth hormone secretagogue* receptor (GHSR) agonist with a K_i of 0.42 nM for GHS-1a** receptor. Relamorelin acetate is centrally penetrant. Relamorelin acetate increases growth hormone levels and accelerates gastric emptying. Relamorelin acetate has the potential for cachexia, gastroparesis, and gastric/intestinal dysmobility disorders research .

HY-14495A

BMS-604992 free base EX-1314 free base	GHSR	Metabolic Disease
BMS-604992 (EX-1314) free base is a selective, orally active small-molecule *growth hormone secretagogue* receptor (GHSR) agonist. BMS-604992 free base demonstrates high-affinity binding (k_i=2.3 nM) and potent functional activity (EC₅₀**=0.4 nM). BMS-604992 free base can stimulate food intake in rodents .

HY-50844

Ibutamoren Mesylate 5 Publications Verification MK-677; MK-0677	GHSR	Endocrinology
Ibutamoren Mesylate (MK-677) is a potent, non-peptide *Growth hormone secretagogue* receptor (GHSR)** agonist. Ibutamoren Mesylate is an orally active growth hormone (GH) secretagogue.

HY-19884B

Relamorelin TFA RM-131 TFA; BIM-28131 TFA	GHSR	Metabolic Disease
Relamorelin (RM-131) TFA, a pentapeptide ghrelin analog, is a selective *ghrelin/growth hormone secretagogue* receptor (GHSR) agonist with a K_i of 0.42 nM for GHS-1a** receptor. Relamorelin TFA is centrally penetrant. Relamorelin TFA increases growth hormone levels and accelerates gastric emptying. Relamorelin TFA has the potential for cachexia, gastroparesis, and gastric/intestinal dysmobility disorders research .

HY-U00433

JMV 2959

2 Publications Verification

GHSR Neurological Disease Endocrinology

JMV 2959 is a growth hormone secretagogue receptor type 1a (GHS-R_1a) antagonist with an IC₅₀ of 32 nM.

JMV 2959 2 Publications Verification	GHSR	Neurological Disease Endocrinology
JMV 2959 is a growth hormone secretagogue receptor type 1a (GHS-R_1a) antagonist with an IC₅₀ of 32 nM.

HY-15243

Capromorelin Tartrate CP 424391-18	GHSR	Neurological Disease Endocrinology
Capromorelin Tartrate is an orally active, potent *growth hormone secretagogue* receptor (GHSR) agonist, with K_i** of 7 nM for hGHS-R1a.

HY-103540

Tabimorelin hemifumarate NN703 hemifumarate	Cytochrome P450	Endocrinology
Tabimorelin (NN703) hemifumarate is an orally active growth hormone (GH) secretagogue. Tabimorelin hemifumarate is also a potent inhibitor of CYP3A4 activity .

HY-15209R

Repaglinide (Standard) AG-EE 623ZW (Standard)	Potassium Channel	Metabolic Disease Cancer
Repaglinide (Standard) is the analytical standard of Repaglinide. This product is intended for research and analytical applications. Repaglinide is an insulin secretagogue for the treatment of type-2 diabetes mellitus .

HY-U00433A

JMV 2959 hydrochloride 2 Publications Verification	GHSR	Neurological Disease Endocrinology
JMV 2959 hydrochloride is a growth hormone secretagogue receptor type 1a (GHS-R_1a) antagonist with an IC₅₀ of 32±3 nM in LLC-PK₁ cells.

HY-101354

R-IMPP PF-00932239	Ser/Thr Protease	Cardiovascular Disease Cancer
R-IMPP (PF-00932239) is an anti-secretagogue of PCSK9 (IC₅₀=4.8 μM), which targets the 80S ribosome to inhibit PCSK9 protein translation .

HY-15242

Capromorelin CP 424391	GHSR	Endocrinology
Capromorelin (CP 424391) is a pyrazolinone-piperidine dipeptide. Capromorelin is an orally active and potent *growth hormone secretagogue* (GHS) (hGHS-R1a K_i=7 nM, rat pituicyte EC₅₀**=3 nM) .

HY-14820

Macimorelin EP-1572; AEZS-130	GHSR	Endocrinology Cancer
Macimorelin (EP-1572), a GH secretagogue, is an orally active GHSR agonist. Macimorelin stimulates GH release. Macimorelin can be used in the research of adult growth hormone deficiency (AGHD), and Cancer anorexia-cachexia syndrome (CACS) .

HY-14820A

Macimorelin acetate EP-1572 acetate; AEZS-130 acetate	GHSR	Neurological Disease Endocrinology Cancer
Macimorelin (EP-1572) acetate, a GH secretagogue, is an orally active GHSR agonist. Macimorelin acetate stimulates GH release. Macimorelin acetate can be used in the research of adult growth hormone deficiency (AGHD), and Cancer anorexia-cachexia syndrome (CACS) .

HY-P1366

des-Gln14-Ghrelin	GHSR	Metabolic Disease
des-Gln14-Ghrelin is a second endogenous ligand for the growth hormone secretagogue receptor. a). des-Gln14-ghrelin potently induces increases in [Ca ²⁺]i in CHO-GHSR62 cells, with an EC₅₀ of 2.4 nM .

HY-P1366A

des-Gln14-Ghrelin TFA	GHSR	Metabolic Disease
des-Gln14-Ghrelin TFA is a second endogenous ligand for the growth hormone secretagogue receptor. a). des-Gln14-ghrelin potently induces increases in [Ca ²⁺]i in CHO-GHSR62 cells, with an EC₅₀ of 2.4 nM .

HY-113906

GSK1614343	GHSR	Metabolic Disease
GSK1614343 is the potent antagonist of growth hormone secretagogues type 1a (GHS1a) receptors. GSK1614343 inhibits the calcium response induced by ghrelin with a pIC₅₀ value of 7.90. GSK1614343 represents a useful tool to investigate the physiological relevance of the ghrelin system in rat models .

HY-19884

Relamorelin RM-131; BIM-28131
Relamorelin (RM-131), a pentapeptide ghrelin analog, is a selective *ghrelin/growth hormone secretagogue* receptor (GHSR) agonist with a K_i of 0.42 nM for GHS-1a** receptor. Relamorelin is centrally penetrant. Relamorelin increases growth hormone levels and accelerates gastric emptying. Relamorelin has the potential for cachexia, gastroparesis, and gastric/intestinal dysmobility disorders research .

HY-15589

GW9508 4 Publications Verification	Free Fatty Acid Receptor Potassium Channel	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
GW9508 is a potent and selective G protein-coupled receptors FFA1 (GPR40) and GPR120 agonist with pEC₅₀s of 7.32 and 5.46, respectively. GW9508 shows ~100-fold selectivity for GPR40 over GPR120. GW9508 is inactive against other GPCRs, kinases, proteases, integrins and PPARs. GW9508 is a glucose-sensitive insulin secretagogue and an ATP-sensitive potassium (K_ATP) channels opener. Anti-inflammatory and anti-atherosclerotic activities .

Relamorelin TFA RM-131 TFA; BIM-28131 TFA	GHSR	Metabolic Disease
Relamorelin (RM-131) TFA, a pentapeptide ghrelin analog, is a selective *ghrelin/growth hormone secretagogue* receptor (GHSR) agonist with a K_i of 0.42 nM for GHS-1a** receptor. Relamorelin TFA is centrally penetrant. Relamorelin TFA increases growth hormone levels and accelerates gastric emptying. Relamorelin TFA has the potential for cachexia, gastroparesis, and gastric/intestinal dysmobility disorders research .

des-Gln14-Ghrelin	GHSR	Metabolic Disease
des-Gln14-Ghrelin is a second endogenous ligand for the growth hormone secretagogue receptor. a). des-Gln14-ghrelin potently induces increases in [Ca ²⁺]i in CHO-GHSR62 cells, with an EC₅₀ of 2.4 nM .

Relamorelin acetate RM-131 acetate; BIM-28131 acetate	GHSR	Metabolic Disease
Relamorelin (RM-131) acetate, a pentapeptide ghrelin analog, is a selective *ghrelin/growth hormone secretagogue* receptor (GHSR) agonist with a K_i of 0.42 nM for GHS-1a** receptor. Relamorelin acetate is centrally penetrant. Relamorelin acetate increases growth hormone levels and accelerates gastric emptying. Relamorelin acetate has the potential for cachexia, gastroparesis, and gastric/intestinal dysmobility disorders research .

des-Gln14-Ghrelin TFA	GHSR	Metabolic Disease
des-Gln14-Ghrelin TFA is a second endogenous ligand for the growth hormone secretagogue receptor. a). des-Gln14-ghrelin potently induces increases in [Ca ²⁺]i in CHO-GHSR62 cells, with an EC₅₀ of 2.4 nM .

Repaglinide-d5
Repaglinide-d₅ is deuterium labeled Repaglinide. Repaglinide is an insulin secretagogue for the treatment of type-2 diabetes mellitus[1].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: